Roche has extended its tender offer period relating to its pending $4.3-billion acquisition of Spark Therapeutics, a Philadelphia-based gene-therapy company, from October 1, 2019 to October 30, 2019. Roche had previously extended the offer period from September 3 to October 1. Roche had announced the acquisition in February 2019.

Roche says the offer was extended to provide additional time for the US Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) to complete their previously disclosed reviews of Roche’s pending acquisition of Spark. The companies say they remain committed to the transaction and are working with the FTC and CMA.

Closing of the tender offer is conditioned upon customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and a tendering of a majority of the outstanding Spark Shares.

Source: Roche